Latest / Ageless and Timeless Podcast® / Peptides, Bioregulators, and the Future of Longevity Science

Transcript

Peptides, Bioregulators, and the Future of Longevity Science · Ageless and Timeless Podcast®

• 0:09
  Speaker 1: Good morning everyone. This is Michelle Hughes from Ageless and Timeless.
• 0:14
  Speaker 1: Today we have a guest who's coming to us from
• 0:16
  Speaker 1: Dubai and boy, I was way off on the time,
• 0:21
  Speaker 1: but it's ten pm there, so her name is Jessica
• 0:24
  Speaker 1: Alana and welcome Jessica.
• 0:27
  Speaker 2: Hi, Hi, Michelle. How you were.
• 0:30
  Speaker 1: So happy to have you here today and thank you
• 0:32
  Speaker 1: for staying up for us.
• 0:34
  Speaker 2: So welcome.
• 0:35
  Speaker 1: Because of the time, yeah, because of the time difference,
• 0:38
  Speaker 1: Jessica's not going to appear on video. We didn't realize
• 0:41
  Speaker 1: it was so late there, so you'll see me and
• 0:46
  Speaker 1: Jessica will stay on an audio, but we are going
• 0:49
  Speaker 1: to have a little presentation later that she prepared, if
• 0:53
  Speaker 1: we don't run out of time first. So we'll see
• 0:56
  Speaker 1: if that works and that will be a video. So, Jessica,
• 1:00
  Speaker 1: I was reading your background and I am so so
• 1:05
  Speaker 1: sorry about your loss with your mother, and i'd like
• 1:08
  Speaker 1: you to tell us a little bit about that history
• 1:11
  Speaker 1: and how that has changed you as a human being,
• 1:14
  Speaker 1: as a person, if you don't mind, Is it okay
• 1:18
  Speaker 1: to talk about it?
• 1:20
  Speaker 2: Yeah, it's okay. I don't mind giving you a brief overview.
• 1:25
  Speaker 2: So I lost my mom in twenty twenty one to
• 1:29
  Speaker 2: mental health issues, and it was a really hard time
• 1:33
  Speaker 2: for me and my family. My mom was actually a major,
• 1:39
  Speaker 2: you know, a major reason for me going into the
• 1:41
  Speaker 2: health industry and getting my biomedicine degree and also my
• 1:46
  Speaker 2: master's and longevity science from Geneva College. So she had
• 1:51
  Speaker 2: a huge inspiration.
• 1:52
  Speaker 1: On my life.
• 1:53
  Speaker 2: And I think, you know, losing someone in that way,
• 1:56
  Speaker 2: it's definitely empowered me to be compassionate and have a
• 2:02
  Speaker 2: lot of empathy, and I think this goes a long
• 2:05
  Speaker 2: way within the health industry.
• 2:08
  Speaker 1: So it's interesting that you didn't go into mental health
• 2:12
  Speaker 1: per se as a result of that tragic event. Do
• 2:17
  Speaker 1: you incorporate mental health with your other protocols that in
• 2:22
  Speaker 1: your consulting practice that you're currently involved.
• 2:25
  Speaker 2: With, Not so much necessarily. I prefer to work with
• 2:32
  Speaker 2: therapies at the cellular level, so peptides and bioregulators and
• 2:36
  Speaker 2: regenerative medicine. I myself, I'm actually a big fan of psychology.
• 2:43
  Speaker 2: It's actually a hobby of mine. I do like reading
• 2:46
  Speaker 2: a lot of psychology books. But I'm not trained nor
• 2:49
  Speaker 2: qualified to work in mental health. So what I stick
• 2:53
  Speaker 2: to is what I know, right.
• 2:55
  Speaker 1: That's perfect well, of course mental health does play a
• 2:59
  Speaker 1: role in every thing in longevity. So and of course
• 3:03
  Speaker 1: we know the gut and the brain access are critical.
• 3:06
  Speaker 1: In fact, today I was just having a conversation about
• 3:09
  Speaker 1: that with one of my colleagues and you know, we're
• 3:13
  Speaker 1: he's having an issue and one of his children, and
• 3:17
  Speaker 1: I said, you know, if you're to deal with depression
• 3:20
  Speaker 1: and anxiety and mental health, you need to start with
• 3:24
  Speaker 1: the gut. And everybody is toxic to some degree if
• 3:29
  Speaker 1: you can't live in today's modern world without being exposed
• 3:33
  Speaker 1: to toksin. So the gut is where you know, ninety
• 3:37
  Speaker 1: eighty seventy to ninety percent of your immune system is
• 3:40
  Speaker 1: in your gut, and all ninety percent of serotonin is
• 3:45
  Speaker 1: made in the gut, so serotonin being feel good like
• 3:49
  Speaker 1: dopamine and the neurotransmitter. So you can't escape this with
• 3:55
  Speaker 1: any of the practice that you're currently doing. So why
• 3:59
  Speaker 1: did you go to Genie vote since you're I mean,
• 4:02
  Speaker 1: you are in Dubai now, But were you in Dubai
• 4:04
  Speaker 1: and then went to Geneva or what exactly was the
• 4:08
  Speaker 1: logistical chronological event?
• 4:13
  Speaker 2: So I have my degree in biomedicine from the UK
• 4:17
  Speaker 2: and then very recently, I've decided to undertake a masters
• 4:21
  Speaker 2: in longevity science. It's actually the world's first Masters in
• 4:25
  Speaker 2: longevity science and it's run by Geneva, Switzerland College. So
• 4:31
  Speaker 2: it can be done remotely or it can be done
• 4:33
  Speaker 2: at the campus. So at the moment, I'm completing the
• 4:37
  Speaker 2: majority of the course remotely and I will go to
• 4:40
  Speaker 2: the campus at some point, maybe to do my hypothesis
• 4:43
  Speaker 2: or maybe to meet my fallow students.
• 4:47
  Speaker 1: Excellent, excellent. So I don't think we have a degree
• 4:51
  Speaker 1: in longevity science in the US at this time, Dewey,
• 4:55
  Speaker 1: do you know.
• 4:56
  Speaker 2: Any I don't think so. I know that Geneva College
• 5:01
  Speaker 2: was the first, so maybe they'll be rolling that out
• 5:05
  Speaker 2: into the US. But we do have a lot of
• 5:07
  Speaker 2: international US students of the Geneva College.
• 5:11
  Speaker 1: Yeah, so that so, what what is the curriculum? Just
• 5:14
  Speaker 1: give us a little taste of what you had to
• 5:17
  Speaker 1: study to get to get to this level.
• 5:22
  Speaker 2: You mean, what's the curriculum inside the inside the master's programs.
• 5:28
  Speaker 1: To earn a master's degree? What kind of court and
• 5:31
  Speaker 1: longevity science? What kind of courses did you have? Do
• 5:34
  Speaker 1: you have to take?
• 5:36
  Speaker 2: So we have to learn about apigenetics, so we have
• 5:39
  Speaker 2: to understand how the mitochondrial DNA works within apigenetics and
• 5:44
  Speaker 2: also messenger DNA. And also I'm actually only a few
• 5:50
  Speaker 2: lectures through the course, but we have some really interesting
• 5:54
  Speaker 2: lecturers and you know, we'll run out PhDs and longevity experts.
• 5:59
  Speaker 2: So I'm still happy. And the cool curriculum is available
• 6:02
  Speaker 2: online for anyone who wants to look at that.
• 6:05
  Speaker 1: Mm hmm. So what what what course did you resonate
• 6:09
  Speaker 1: with the most?
• 6:12
  Speaker 2: Actually I'm only a few lectures through, so I'm still
• 6:17
  Speaker 2: working my way through. But I really like learning about
• 6:20
  Speaker 2: the messenger RNA when it comes to anti aging.
• 6:26
  Speaker 1: Yeah, you know, the DNA Company is one of my
• 6:31
  Speaker 1: very close colleagues. Are you familiar with them? They do
• 6:35
  Speaker 1: the epigenetic testing in Toronto.
• 6:39
  Speaker 2: Yeah, I know quite a few, quite a few epigenetic
• 6:42
  Speaker 2: taxting companies.
• 6:44
  Speaker 1: Right, Well, that one, I think is probably the number
• 6:46
  Speaker 1: one because they do they never sell your data. You know,
• 6:49
  Speaker 1: they're uh, you know, you know twenty three and me
• 6:53
  Speaker 1: is going bankrupt or has gone bankrupt. But you know,
• 6:56
  Speaker 1: most of these companies have been guilty of using your
• 7:00
  Speaker 1: data and you're you know, without your knowledge. So this
• 7:04
  Speaker 1: is a big issue. In genetic testing and epigenetic testing.
• 7:09
  Speaker 1: So DNA company absolutely number one does not use your data.
• 7:15
  Speaker 1: It's all private, and then they send you your results
• 7:18
  Speaker 1: in a sixty page test result where you can also
• 7:23
  Speaker 1: then have an app that you go online because it's
• 7:26
  Speaker 1: very I don't know how you feel, Jessica, maybe you
• 7:29
  Speaker 1: could tell us, but it's kind of daunting because they
• 7:32
  Speaker 1: have all these different genes that with all these different labels,
• 7:36
  Speaker 1: and when you're a lay person trying to understand what
• 7:40
  Speaker 1: these genes are and how you know what they represent,
• 7:45
  Speaker 1: you'd need a year long course just to study that,
• 7:49
  Speaker 1: I think so. But this app allows you to go
• 7:54
  Speaker 1: online and look onder headings like cardiovascular health or brain
• 7:58
  Speaker 1: health or gut health, and then under that they have
• 8:03
  Speaker 1: the genes that are corresponding with those areas those categories,
• 8:08
  Speaker 1: and then they tell you whether you are optimal suboptimal.
• 8:13
  Speaker 1: But the big thing, and this is something that I'm
• 8:16
  Speaker 1: sure you're learning and your your courses, you don't have
• 8:20
  Speaker 1: to be like it doesn't have to be like a
• 8:23
  Speaker 1: sentence of death and destruction if you get a suboptimal
• 8:28
  Speaker 1: epigenetic rating on any one of these measurements, because epigenetic
• 8:35
  Speaker 1: means lifestyle. So if you're genetically you have one, you know,
• 8:41
  Speaker 1: a suboptimal gene, that doesn't mean it's going to get expressed.
• 8:46
  Speaker 2: Yes, it's true, it's dicorrect. It's based on histone modifications
• 8:51
  Speaker 2: and methylation and some other transcription and translation factors as
• 8:57
  Speaker 2: to while the genome will be expressed and all. So
• 9:00
  Speaker 2: if it is happy genetic, you can positively influence that
• 9:03
  Speaker 2: by regenerative medicine and lifestyle modifications, good food, good diet,
• 9:09
  Speaker 2: good relationships and that type of thing.
• 9:12
  Speaker 1: And that's everything that they go through with you, you know,
• 9:15
  Speaker 1: and they did what they have follow ups. You're nice, Yeah,
• 9:19
  Speaker 1: you know, I know. I connected you with doctor Bill Lawrence.
• 9:23
  Speaker 1: We'll talk about the peptide bioregulators. But i'd love to
• 9:27
  Speaker 1: connect you with Kashif Khan and who is the co
• 9:31
  Speaker 1: founder or founder actually and Tracy Wood is the current CEO.
• 9:37
  Speaker 1: Kashif stepped aside to be business development, but I'd love
• 9:41
  Speaker 1: to connect you. I think they'd be an incredible contact
• 9:46
  Speaker 1: influence for you as you're going through your coursework. So
• 9:49
  Speaker 1: if you want that after offline, I'll be happy to
• 9:53
  Speaker 1: I'll be happy to send send it a digital introduction
• 9:56
  Speaker 1: for you.
• 9:58
  Speaker 2: Oh, that would be amazing, thank you, so lunch, Well,
• 10:00
  Speaker 2: they probably appreciate tide, you.
• 10:02
  Speaker 1: Know, Jessica. They probably want you to take the test
• 10:05
  Speaker 1: and then use that as a benchmark for you know,
• 10:09
  Speaker 1: relationship going forward, which is exactly what I did. So yeah, anyway,
• 10:15
  Speaker 1: well we'll talk about that later. So European Wellness, founded
• 10:18
  Speaker 1: by the iconic and widely published professor doctor Michael Chan,
• 10:23
  Speaker 1: is the world leader in stem cell and peptide therapy,
• 10:26
  Speaker 1: with twenty six medical and aesthetics BA locations primarily in
• 10:30
  Speaker 1: Europe and Asia. Their website www. Dot Europeanwellness dot com
• 10:36
  Speaker 1: details the wide range of wellness products that can be
• 10:39
  Speaker 1: ordered using the age's code for a ten percent discount.
• 10:44
  Speaker 1: They will also offer our viewers discounts on medical and
• 10:47
  Speaker 1: cosmetic services and products that they choose to visit the clinics.
• 10:51
  Speaker 1: I have firsthand experience using their wide range of science
• 10:55
  Speaker 1: based stem cell and peptide products and are now a
• 10:58
  Speaker 1: loyal customer. Go to their website Www. European Wellness dot
• 11:04
  Speaker 1: com for more information about this exciting company. Let's jump
• 11:11
  Speaker 1: forward to the most important issue that brought us together,
• 11:18
  Speaker 1: and that's peptide bioregulators. This is like probably one of
• 11:23
  Speaker 1: the hottest topics today in functional medicine and peptizing general,
• 11:29
  Speaker 1: but more specifically and more narrowly peptide bioregulators. So what
• 11:35
  Speaker 1: was it that brought you to that awareness so that
• 11:38
  Speaker 1: you reached out to me to introduce you to Bill Lawrence.
• 11:43
  Speaker 2: So I've been working in the regenerative Madison space since
• 11:48
  Speaker 2: twenty twenty one, and I actually started off with hyperbioical
• 11:53
  Speaker 2: oxygen therapy. So I was working in the Wellness Lab,
• 11:57
  Speaker 2: which is number one hypak in London, and they had
• 12:01
  Speaker 2: some very beautiful hyperbaric oxygen machines. And after learning about
• 12:05
  Speaker 2: hyperbaric oxygen, I became very interested in other ajubant therapies
• 12:11
  Speaker 2: and one of these being peptides. So peptides are typically
• 12:15
  Speaker 2: between four and fifty amino acids and chain land and
• 12:20
  Speaker 2: once I kind of figured out peptides, I stumbled on
• 12:25
  Speaker 2: to bioregulators. And I actually got to know bioregulators from
• 12:30
  Speaker 2: a very good friend of mine, Dean Henry.
• 12:34
  Speaker 1: Maybe you know him.
• 12:35
  Speaker 2: He's the founder of U A E Peptides and he
• 12:38
  Speaker 2: knows doctor Cavinston very well. You know he knew him,
• 12:42
  Speaker 2: and yeah, so Dean actually introduced me to the oral
• 12:47
  Speaker 2: peptide oral peptid bioregulators. And in the beginning I was
• 12:51
  Speaker 2: kind of confused because there wasn't too much literature on them.
• 12:56
  Speaker 2: This was early twenty twenty three, and they were harmy
• 13:00
  Speaker 2: being touched upon in early twenty twenty three, and most
• 13:05
  Speaker 2: of the literature I found with either a Russian translation
• 13:09
  Speaker 2: or it was from Russia or Ukraine or those eastern
• 13:14
  Speaker 2: European countries, and it was hard to find, you know,
• 13:17
  Speaker 2: any literature or second in the third hand writing about
• 13:21
  Speaker 2: the oral pepti bioregulators within the West. So I kind
• 13:24
  Speaker 2: of I kind of figured out that, you know, at
• 13:27
  Speaker 2: their core, their appy genetic switches, and then I found
• 13:32
  Speaker 2: some interesting presentations, and then I stumbled across well, of course,
• 13:37
  Speaker 2: I found the Calvenston's work on PubMed, and in the
• 13:40
  Speaker 2: beginning I wasn't even sure if his work was available
• 13:44
  Speaker 2: on part MAD, but actually, you know, in the end,
• 13:46
  Speaker 2: I did do a pub Med search on his name,
• 13:49
  Speaker 2: and it brings back all of his studies in English,
• 13:52
  Speaker 2: and also his website, I think it's Calvinston dot info
• 13:56
  Speaker 2: has all of the studies in English as well. So
• 13:59
  Speaker 2: then in the end I just stumbled across the research.
• 14:02
  Speaker 2: And then one of the biggest advocators of peptide bioregulators
• 14:07
  Speaker 2: in the US, and an individual who was carrying on
• 14:11
  Speaker 2: all of the knowledge in doctor Cabinston's work, is doctor
• 14:14
  Speaker 2: Bill Lawrence. So I listened to your podcast with him,
• 14:18
  Speaker 2: which I thought was absolutely amazing. I'd never heard of
• 14:22
  Speaker 2: the oral peptide bioregulators being talked about in so much
• 14:26
  Speaker 2: debt by a Western PhD or Western doctor, so for
• 14:31
  Speaker 2: me that was very interesting.
• 14:35
  Speaker 1: And didn't you you've joined his clinical trials.
• 14:39
  Speaker 2: Correct, I have, that's right, I haven't. I recommended a
• 14:44
  Speaker 2: lot of people to join his trials as well. I
• 14:47
  Speaker 2: told a lot of my close friends and my community.
• 14:50
  Speaker 2: I'm pretty sure more than a handful of joined, So
• 14:54
  Speaker 2: I think there was a good outcome for everyone.
• 14:56
  Speaker 1: Oh good, I knew. He said that there were a
• 14:59
  Speaker 1: couple of people I think from Geneva, right, your associates.
• 15:04
  Speaker 2: Yeah, yeah, a few people from Switzerland, some friends from
• 15:08
  Speaker 2: Norway as well. I think maybe some people from Dubai
• 15:11
  Speaker 2: in the UK too.
• 15:13
  Speaker 1: Oh okay, So I didn't know that. He's been very
• 15:17
  Speaker 1: transparent with me about all the work he's doing because
• 15:21
  Speaker 1: I'm in his clinical trials. I've been in for I
• 15:24
  Speaker 1: think it's two years now, and I just took my
• 15:27
  Speaker 1: second test. You took the true diagnostics and the spectro
• 15:31
  Speaker 1: cell correct.
• 15:33
  Speaker 2: I haven't yet. I've been a little busy, but I
• 15:38
  Speaker 2: definitely will soon.
• 15:40
  Speaker 1: Yeah, in order for him to start working with you.
• 15:42
  Speaker 1: Those are the baselines. So just so everybody, anybody that's listening,
• 15:47
  Speaker 1: if you are in the medical field. He has a
• 15:51
  Speaker 1: clinical trial doctor Bill Lawrence in Atlanta, Georgia. He's absolutely
• 15:57
  Speaker 1: does not want people to call him directly, so I
• 16:00
  Speaker 1: to screen everybody because he's so busy. I mean, you
• 16:03
  Speaker 1: can imagine with over one hundred people in his clinical
• 16:07
  Speaker 1: trials and he's following everybody. But he does tell me
• 16:12
  Speaker 1: that if I have anybody that is interested that's in
• 16:16
  Speaker 1: the medical world, because there is a fee, as you know, Jessica,
• 16:22
  Speaker 1: to be in the clinical trials, and it's a lower
• 16:26
  Speaker 1: fee if you're a medical professional. There's still a concierge
• 16:32
  Speaker 1: clinical trial position for a consumer, but the fee is
• 16:38
  Speaker 1: much higher. So I don't even encourage anybody who's not
• 16:41
  Speaker 1: a medical professional, but if you are, you're interested in
• 16:45
  Speaker 1: either way, you can always reach me at my Ageless
• 16:50
  Speaker 1: and Timeless website. There's a phone number and an email.
• 16:55
  Speaker 1: But anyway, moving on, the true diagnostics is a methylation measurement,
• 17:02
  Speaker 1: so it gives you your biological age versus your chronological age,
• 17:07
  Speaker 1: which we'll talk about in just a moment, because that's
• 17:10
  Speaker 1: a key element to the baseline for beginning these peptide bioregulators.
• 17:16
  Speaker 1: And then you know, it measures your DNA methylation, which
• 17:20
  Speaker 1: it means you know your toxicity level and how your
• 17:26
  Speaker 1: epigenetics or your genetics affect your how quickly you methylate.
• 17:32
  Speaker 1: And I don't know about you, but I found out
• 17:36
  Speaker 1: from doing the DNA test that I'm a slow methy later,
• 17:40
  Speaker 1: so that gene was suboptimal. The good news was that
• 17:44
  Speaker 1: the APO four, which is the Alzheimer's that was normal
• 17:49
  Speaker 1: the Alzheimer's gene, and then the there was another one
• 17:54
  Speaker 1: that they do that was normal, which was a big one.
• 17:57
  Speaker 1: I can't remember which which one it was, but it was.
• 17:59
  Speaker 1: So it was such a relief to have. So I
• 18:02
  Speaker 1: wasn't surprised about the methylation because I think a lot
• 18:08
  Speaker 1: of people have that suboptimal gene. Again because of the
• 18:13
  Speaker 1: toxicity in our world, it's very unusual to find people
• 18:17
  Speaker 1: who can get rid of toxins on based on just
• 18:20
  Speaker 1: on their genetics. So there has to be a lot
• 18:23
  Speaker 1: more to it than the lifestyle, as we both know.
• 18:27
  Speaker 1: But then the other tests, the spectro cell test measures
• 18:30
  Speaker 1: your telomere length. And if anyone is following this, it
• 18:37
  Speaker 1: had been listened to my other podcasts, you know that
• 18:41
  Speaker 1: your telomeres, and Jessica can certainly confirm this. They're really
• 18:46
  Speaker 1: one measurement of your biological aging. So, Jessica, why don't
• 18:51
  Speaker 1: you explain what a telomir is.
• 18:54
  Speaker 2: Yeah, So, tlomeir is all the protective caps at the
• 18:58
  Speaker 2: end of chromosomes that basically stop the double helix DNA
• 19:03
  Speaker 2: from unraveling. And essentially, so if you can imagine a shoelace,
• 19:09
  Speaker 2: you know that plastic protective cap at the end of
• 19:12
  Speaker 2: a shoelace, you know, obviously protects the shoelace strands from unraveling. Well,
• 19:18
  Speaker 2: as you age, those protective chromosome caps telomere caps which
• 19:24
  Speaker 2: protect the chromosomes become more degraded and just get shorter
• 19:28
  Speaker 2: and shorter, and therefore the chromosomes begin to unravel, and
• 19:32
  Speaker 2: this basically translates into faulty genome processing, and therefore you
• 19:39
  Speaker 2: have mistranslation of proteins. And you know, as you know,
• 19:42
  Speaker 2: the mistranslation of proteins is kind of where a lot
• 19:45
  Speaker 2: of aging and disease begins.
• 19:48
  Speaker 1: Yeah. I think that's a really, very very good description,
• 19:51
  Speaker 1: and I think the simplest way to say that. Look,
• 19:53
  Speaker 1: in this case, longer is better. You don't want short telomeres.
• 19:58
  Speaker 1: That means you're da is splitting and you're getting getting
• 20:02
  Speaker 1: every time there's a cellular DNA or telomere split, they
• 20:08
  Speaker 1: get shorter. But the longer they are, the younger you are.
• 20:12
  Speaker 1: Is that a fair simplistic way to say it.
• 20:16
  Speaker 2: Yeah, of course. And actually today there's only I think
• 20:22
  Speaker 2: two therapies that have shown significant impact on increasing telomere
• 20:28
  Speaker 2: land and the first one is hyperbaric oxygen, so this
• 20:32
  Speaker 2: was shown by the Israeli group led by doctor Shia Frtti.
• 20:37
  Speaker 2: And the second one is the bioregulator appitalent.
• 20:42
  Speaker 1: Right exactly. Yeah, for a while, there was the TA
• 20:46
  Speaker 1: sixty five, if you remember, and everybody was touting you
• 20:49
  Speaker 1: go to the shows, and they were always there was.
• 20:52
  Speaker 2: Always I hadn't heard of that.
• 20:54
  Speaker 1: Maybe that was my era, and I think if you
• 20:56
  Speaker 1: talk to Bill Lawrence, she'll tell you that the peptide
• 20:59
  Speaker 1: by regulators are one of the ways to lengthen your telomeres.
• 21:04
  Speaker 1: And that's why they do the baseline because they want
• 21:07
  Speaker 1: to see how the peptides will affect over over time. So, yeah,
• 21:14
  Speaker 1: you know, that was the one great thing. When I
• 21:16
  Speaker 1: did it originally with Bill back two years ago, he
• 21:21
  Speaker 1: said he had to send the test back to spectro
• 21:23
  Speaker 1: cell because he never had a result with someone chronologically
• 21:28
  Speaker 1: of my age that was so biologically my telomeres were
• 21:33
  Speaker 1: an infant of one to five years old or zero
• 21:37
  Speaker 1: infant of five years old. He said he couldn't believe
• 21:39
  Speaker 1: the results, so he sent it back to see if
• 21:41
  Speaker 1: they had made a mistake, and sure enough they didn't.
• 21:45
  Speaker 1: They hadn't. So we'll see what this current one after
• 21:49
  Speaker 1: two years, what the current one does. But that was
• 21:54
  Speaker 1: like a really good outcome. Well, let's talk about biological
• 21:58
  Speaker 1: and chronological age. And just before we leave that subject,
• 22:03
  Speaker 1: I just want to say, because we'll come back to
• 22:07
  Speaker 1: the general subject of peptide bioregulators, but just so everybody
• 22:11
  Speaker 1: understands what Jessica just said is the bio peptides are
• 22:17
  Speaker 1: amino acids, so the peptide bioregulators have fewer amino acids,
• 22:23
  Speaker 1: usually less than fifteen, whereas the other peptides that you're
• 22:27
  Speaker 1: hearing so much about that are usually injectable, although they're
• 22:31
  Speaker 1: coming more and more becoming more and more available as
• 22:35
  Speaker 1: nasal sprays and some oral integrative integrative peptides that they'll
• 22:43
  Speaker 1: be on my podcast in a couple of weeks. Lori
• 22:46
  Speaker 1: and Kent Holdsorf they do the oral version. But anyway,
• 22:51
  Speaker 1: the differences between peptides generally and peptide bioregulators are the
• 22:57
  Speaker 1: number of amino acids and that the yan regulators are
• 23:02
  Speaker 1: all oral, whereas the general peptides like ipra morelen and
• 23:09
  Speaker 1: sam marellen and you know all the others, even insulin.
• 23:14
  Speaker 1: If people know that the original peptide is insulin, correct, Jessica.
• 23:21
  Speaker 2: Yeah, in the nineteen forties, I'm pretty sure they developed insulin,
• 23:25
  Speaker 2: and yeah, that was the original founding peptide.
• 23:29
  Speaker 1: Nobody ever knew or did anything with pep guides until
• 23:33
  Speaker 1: about ten years ago, right, So then now they've become
• 23:36
  Speaker 1: the darling of the longevity world, as I mentioned, And
• 23:40
  Speaker 1: so just so you know, if you're doing peptid bioregulators,
• 23:45
  Speaker 1: which you can get this. Doctor Cavinson is the.
• 23:49
  Speaker 2: Original original, Yeah, and he.
• 23:52
  Speaker 1: Was assigned to that role by Putin. That doesn't diminish
• 23:58
  Speaker 1: his impact as he could have. He could have won
• 24:00
  Speaker 1: a Nobel Prize. I don't know why he didn't, but
• 24:03
  Speaker 1: he's unfortunately passed away last year, so it would have
• 24:09
  Speaker 1: to be posthumous now. But he was assigned because of
• 24:14
  Speaker 1: Chernobyl and because the astronauts and they were seeing more
• 24:18
  Speaker 1: and more toxicity and these people that and the athletes too,
• 24:25
  Speaker 1: So he said, we want to find a way to
• 24:29
  Speaker 1: address this problem, and Caviinson was given that assignment. And
• 24:34
  Speaker 1: so just a little history if anyone wants to know
• 24:36
  Speaker 1: that Bill Lawrence being who the kind of guy he is,
• 24:40
  Speaker 1: he's like incredibly proactive, and he had a family history
• 24:44
  Speaker 1: of early demise and he was at that time, I
• 24:48
  Speaker 1: think when he first started looking into this, he was
• 24:51
  Speaker 1: in his seventies early seventies, and most of his family
• 24:54
  Speaker 1: had passed away before they ever reached mid seventies. So
• 24:58
  Speaker 1: he said, I don't want this to be my fate,
• 25:00
  Speaker 1: and I want to find the answers. And he's a
• 25:03
  Speaker 1: very successful real estate developer, just like you know. He
• 25:06
  Speaker 1: and I have the same background and came to functional
• 25:10
  Speaker 1: medicine and you know, very different ways. But his was
• 25:14
  Speaker 1: really because of his personal challenge of wanting to extend
• 25:19
  Speaker 1: his life. And so he discovered Cavinson just like you did.
• 25:23
  Speaker 1: You know, you discovered him, and he's researched it, and
• 25:25
  Speaker 1: to his credit, he got on an airplane and went
• 25:28
  Speaker 1: to the Soviet Union to Saint Petersburg, knocked on the
• 25:32
  Speaker 1: door and took Cavinson's credit. They took him in and
• 25:36
  Speaker 1: they trained him, and they they saw him as a
• 25:39
  Speaker 1: real opportunity to expand the peptipe by regulators in the
• 25:44
  Speaker 1: United States, which at that time they had been forty
• 25:47
  Speaker 1: years in the in Russia but sold in drug stores,
• 25:52
  Speaker 1: I mean, you know, easily obtained. So doctor Bill Lawrence,
• 26:00
  Speaker 1: who is a PhD, not a medical doctor, became the
• 26:05
  Speaker 1: spokesperson and the steward for expanding the peptides here in
• 26:10
  Speaker 1: the US. So that's just a little bit of background.
• 26:15
  Speaker 1: And by the way, they the other thing about the bioregulators,
• 26:19
  Speaker 1: they address individual organs. So let's just say, Jessica, you
• 26:24
  Speaker 1: know this because you know, Bill designs the protocol when
• 26:30
  Speaker 1: you're in his clinical trials according to your testing. And
• 26:35
  Speaker 1: so if he sees and he asks you interviews you
• 26:39
  Speaker 1: as well. But if he sees that you have a
• 26:42
  Speaker 1: weakness in let's say your heart, he'll design the program
• 26:48
  Speaker 1: to focus more on the peptides that target the heart.
• 26:52
  Speaker 1: So in a way, they're like stem cells that are pluripotent.
• 26:55
  Speaker 1: They they target the organ that most needs to be
• 27:02
  Speaker 1: addressed because of them its weakness. So every person is customized.
• 27:08
  Speaker 1: So you'll find that as you get going with him
• 27:10
  Speaker 1: that he'll be interviewing you so that you'll know exactly
• 27:14
  Speaker 1: how to customize your program. And you normally you take
• 27:17
  Speaker 1: the peptides ten days a month, so ten days on,
• 27:22
  Speaker 1: twenty days off, so and during that time we take
• 27:26
  Speaker 1: probably five to six or seven different peptides and orally
• 27:33
  Speaker 1: and then for ten days and then you take a
• 27:36
  Speaker 1: rest and then come back to them after the next round.
• 27:41
  Speaker 1: So yeah, there will be interesting. This will be my
• 27:45
  Speaker 1: way of telling you. I'll come back to you and
• 27:47
  Speaker 1: to my viewers to let you know how they have
• 27:52
  Speaker 1: affected my personal journey where you know, a very healthy
• 27:58
  Speaker 1: person is doing this without health issues. So I'll be
• 28:02
  Speaker 1: interested to seeing going back now to the biological versus chronological,
• 28:08
  Speaker 1: So tell me what your definition of chronological versus biological
• 28:13
  Speaker 1: aging is and how you would guide people to understand
• 28:18
  Speaker 1: how important knowing your biological age is in your health journey.
• 28:24
  Speaker 2: Yeah, so chronological age is pretty simple to define and
• 28:31
  Speaker 2: explain and understand, and it's basically the number of years
• 28:35
  Speaker 2: that you've lived on planet Earth. So chronological age is
• 28:39
  Speaker 2: pretty easy. Biological age is a bit more complex, but
• 28:44
  Speaker 2: basically it's the age that yourself tissues organs and system
• 28:49
  Speaker 2: and behaving as. But even biological age can be classified
• 28:54
  Speaker 2: into immune age, cognitive age, anabolic age, all these different
• 29:01
  Speaker 2: further classifications, and also the way that biological age is
• 29:05
  Speaker 2: measured can also be further classified. So some people would
• 29:10
  Speaker 2: rather take an epigenetic clock as we've spoken about based
• 29:14
  Speaker 2: on DNA metholations happens. Other people will take a talomeal lens.
• 29:19
  Speaker 2: Some people will look at the glycans, so the balance
• 29:22
  Speaker 2: of pro inflammatory and anti inflammatory glycans. And with AI
• 29:27
  Speaker 2: and all this deep learning, you know, there's so many
• 29:30
  Speaker 2: new ways to combine multiple blood markers to bring out
• 29:34
  Speaker 2: an overall you know, biological age. So biological age is
• 29:38
  Speaker 2: a bit more complex and in of itself, it's a
• 29:41
  Speaker 2: whole topic and concept to understand, but essentially it's the
• 29:46
  Speaker 2: kind of numerical age that your cells are behaving as,
• 29:50
  Speaker 2: which obviously dictates you know the system and proxy you
• 29:54
  Speaker 2: use an individual.
• 29:56
  Speaker 1: Yes, And we say every time we get into the
• 29:59
  Speaker 1: subject that you you are as old as yourself. So
• 30:02
  Speaker 1: all aging begins and ends in the cells. But however,
• 30:06
  Speaker 1: true diagnostics, which measures the DNA methylation, is now technologically
• 30:12
  Speaker 1: so advanced that they've added a way when you do
• 30:17
  Speaker 1: their blood test to measure the health of each of
• 30:21
  Speaker 1: your organs. Now I don't yeah, that's going to be
• 30:24
  Speaker 1: exciting if you haven't done that test yet. I just
• 30:27
  Speaker 1: did it yesterday, the second time, So the first time
• 30:31
  Speaker 1: they didn't have that available. So now they've combined two protocols,
• 30:36
  Speaker 1: the original with the new one that will tell you
• 30:40
  Speaker 1: so much more information that measures up and then they'll
• 30:43
  Speaker 1: give you a number of how all this tallies up
• 30:46
  Speaker 1: to your biological age. So very exciting. What's happening. An AI,
• 30:52
  Speaker 1: of course has been a big part of this, but
• 30:55
  Speaker 1: they've been working with some of the leading I think
• 30:58
  Speaker 1: it's Cornell University is where they doing a lot of
• 31:00
  Speaker 1: their research. So yeah, so this is something everybody should
• 31:06
  Speaker 1: be aware. I think everyone should take that true diagnostic test, honestly.
• 31:10
  Speaker 3: Now there are others, but I think they're the leader
• 31:13
  Speaker 3: in the field, and that's why you know, doctor Lawrence
• 31:17
  Speaker 3: uses them exclusively for his baseline.
• 31:22
  Speaker 1: So you mentioned the in terms of the UH, the
• 31:29
  Speaker 1: the biological age that the cells are so important, and
• 31:34
  Speaker 1: so I don't know yet whether true diagnostic is able
• 31:38
  Speaker 1: to measure the health of your cells. That's something I
• 31:41
  Speaker 1: would need to ask them. The health of your organs
• 31:44
  Speaker 1: is a you know, key indicator of the health of
• 31:46
  Speaker 1: your body, but whether it goes into the mitochondria and
• 31:51
  Speaker 1: the atp of that, I don't know. Are you Are
• 31:53
  Speaker 1: you aware of anyone that's doing the measuring your the
• 31:57
  Speaker 1: health of your cells.
• 31:59
  Speaker 2: I don't know anyone who's doing that commercially. But I
• 32:04
  Speaker 2: think if there was a way to look at how
• 32:07
  Speaker 2: your mitochondrial DNA is being expressed, which is a whole
• 32:12
  Speaker 2: other part of the geno, we think that possibly could
• 32:16
  Speaker 2: be a good indicator. I think there's tasks out there
• 32:21
  Speaker 2: which can give a rough estimation of how much atp
• 32:27
  Speaker 2: SHO a dynascene tried phosphate yourselves are making, but I
• 32:31
  Speaker 2: don't think it's it's very accurate, like you're more likely
• 32:35
  Speaker 2: to get a false positive. I think mitochondrial DNA, if
• 32:41
  Speaker 2: someone can measure that, then then that that could be
• 32:45
  Speaker 2: what a good outcome, you know.
• 32:48
  Speaker 1: I think the DNA companies does measure, but it's just
• 32:52
  Speaker 1: pure genetics, which we both know is not a you know, yeah,
• 32:58
  Speaker 1: that can be altered by your lifestyle. So I don't
• 33:01
  Speaker 1: know if it's completely giving you the biological or the
• 33:04
  Speaker 1: meta the biophysical uh, measurement of your cells. That's something
• 33:10
  Speaker 1: that we need to check into that. So which of
• 33:14
  Speaker 1: the peptizers had the most scientific backing in your experience?
• 33:21
  Speaker 2: I think thimos and alpha one, So timosinal for one,
• 33:26
  Speaker 2: it is a FDA approved I'm unvaccinated, so it's not
• 33:32
  Speaker 2: that you know, these governing medical bodies have too much
• 33:36
  Speaker 2: influence on my train of thought. But if something is
• 33:39
  Speaker 2: aftera approved, then you know by proxy it has a
• 33:43
  Speaker 2: lot of clinical you know, human clinical trials. So I
• 33:47
  Speaker 2: know that thimosin alpha one is patented under the drug Namesadaxin,
• 33:51
  Speaker 2: and it's owned or was owned by Cycling Pharmaceuticals, which
• 33:55
  Speaker 2: is worth a couple of one hundred million dollars. So
• 33:58
  Speaker 2: I know that themUS and alpha one has a lot
• 34:02
  Speaker 2: of clinical backing, So in my opinion, it would be
• 34:06
  Speaker 2: pemos and alpha one, which isn't the most raved about
• 34:09
  Speaker 2: peptide because it solely focuses on the thymus gland and
• 34:13
  Speaker 2: the immune system, which is my favorite topic. Everyone loves
• 34:17
  Speaker 2: BPC one five salent, right, but simos and one is
• 34:21
  Speaker 2: probably the one with the most backing.
• 34:25
  Speaker 1: Well, and keep in mind, for anybody that's watching today,
• 34:30
  Speaker 1: what Jessica's talking about are the regular the peptides, Yeah,
• 34:36
  Speaker 1: not the peptide bioregulators. However, the peptide bioregulators have targeted
• 34:43
  Speaker 1: the thymus gland. There is one Russian name you know,
• 34:48
  Speaker 1: translates over to the thymus gland, just as there's another
• 34:51
  Speaker 1: one for the bone marrow and so forth. So again
• 34:57
  Speaker 1: keep in mind, these are two distinct categories of peptides,
• 35:01
  Speaker 1: so the thymbras and alpha one in the normal peptide,
• 35:06
  Speaker 1: the original peptide is usually injectable, although have you seen
• 35:12
  Speaker 1: that there are more and more available now to take orally?
• 35:17
  Speaker 2: Yeah, I have a little bit of an issue with
• 35:23
  Speaker 2: the mass production of oral available peptides. For example, I
• 35:28
  Speaker 2: saw an advertisement of orally available SS thirty one. Now
• 35:35
  Speaker 2: SS thirty one is a synthetic, you know, quite fragile
• 35:40
  Speaker 2: mitochondrial peptide that is involved in repairing the in a
• 35:44
  Speaker 2: mitochondrial membrane, and I don't think it's commercially ethical to
• 35:51
  Speaker 2: sell a product which I don't think will have a
• 35:55
  Speaker 2: high uptake into the mitochondria via an oral route, considering
• 36:01
  Speaker 2: it's difficult for most pathtides to even act on cells,
• 36:06
  Speaker 2: let alone go inside the cell and reach the mitochondria
• 36:10
  Speaker 2: to work. So I know that some peptides are very
• 36:15
  Speaker 2: good orally for example lorazatide BBC on five salven kpv,
• 36:21
  Speaker 2: but some of the more specific peptides that with intrasalular
• 36:27
  Speaker 2: sorry within the cells or intracelluar exalular I don't necessarily
• 36:32
  Speaker 2: think that these should be made oral. And to make
• 36:35
  Speaker 2: the distinction that you were saying, the peptides that are
• 36:39
  Speaker 2: injectable typically are between four and fifty in chain land,
• 36:44
  Speaker 2: and then the oral peptide bioregulators developed by doctor Carvinston
• 36:49
  Speaker 2: between two and four in chain land. For anyone watching
• 36:53
  Speaker 2: the distinction comes from the chain land for the amount
• 36:56
  Speaker 2: of amino acids in the chain. So that's typically the
• 36:59
  Speaker 2: hard line that we put ye.
• 37:02
  Speaker 1: Yes, So going back to the cymosene alpha that's you know,
• 37:06
  Speaker 1: historically originally was targeting for the immune system. Correct.
• 37:13
  Speaker 2: Yeah, it's twenty eight amino acids long, and actually it's
• 37:17
  Speaker 2: a bioidentical peptide. So you're born with timos and alpha one,
• 37:22
  Speaker 2: so your body makes thimost and alpha one as a
• 37:25
  Speaker 2: regular part of homeostasis. And as you age or you
• 37:29
  Speaker 2: become you know, impacted by toxins, or maybe you become
• 37:33
  Speaker 2: chronically sick with a virus, something like long covid or
• 37:37
  Speaker 2: lime disease or mol toxicity, your natural indulgenous production of
• 37:42
  Speaker 2: thymosin alpha one decreases and you have thymic involution and
• 37:46
  Speaker 2: thymaxnessence lone natural killer cells. It's like a domino effect.
• 37:51
  Speaker 2: So when you use dimos and alpha one as a
• 37:54
  Speaker 2: bioidentical supplement and you inject this as a peptide, all
• 37:59
  Speaker 2: you're doing is invoking the immune cascades that should already
• 38:03
  Speaker 2: be occurring in your body, but it's not because you're
• 38:06
  Speaker 2: not well.
• 38:07
  Speaker 1: Right, Yeah, I think a lot of people who have
• 38:10
  Speaker 1: had long COVID have been resorting to building back your
• 38:15
  Speaker 1: immune system using that peptide.
• 38:17
  Speaker 2: Oh yeah, yeah, it's super common in the long COVID world.
• 38:21
  Speaker 1: And BPC one fifty seven is you know, that's probably
• 38:24
  Speaker 1: the most prevalent, and that's actually made in your gut.
• 38:28
  Speaker 1: That's why there are two forms of BPC one fifty seven.
• 38:31
  Speaker 1: One it targets your joint health and the other one
• 38:34
  Speaker 1: targets your gut health. And so you can actually take
• 38:37
  Speaker 1: one peptide and basically try to get results on two fronts.
• 38:44
  Speaker 1: But what do you think of that peptide? Have you
• 38:47
  Speaker 1: seen it work with some of the people that you
• 38:49
  Speaker 1: work with.
• 38:51
  Speaker 2: Yeah, I really like BPC one pat seven. So it's
• 38:55
  Speaker 2: primarily spoken about in disgust for the gut and also
• 39:01
  Speaker 2: for ligaments and soft tissue and joints, as you said,
• 39:04
  Speaker 2: but also it actually blocks eMac so it actually has
• 39:10
  Speaker 2: been proven to basically repair the voltage gated ion channels
• 39:14
  Speaker 2: within cells. So yeah, it's very beneficial at the salular level,
• 39:20
  Speaker 2: and also it's neuroprotective. It actually balances the dopamine and
• 39:27
  Speaker 2: serotonin receptors, and it's also very good for the vegus
• 39:30
  Speaker 2: new As you said, all of the peptides are omnipotent, pluripotent,
• 39:37
  Speaker 2: pleotropic in nature, so you know they have so many
• 39:42
  Speaker 2: different benefits, ten plus benefits per peptide. So if you
• 39:47
  Speaker 2: take a staff of peptides, so you take five different
• 39:50
  Speaker 2: peptides all in one protocol, you're going to have, you know,
• 39:54
  Speaker 2: so many benefits like ten to the to a high
• 39:57
  Speaker 2: numerical value because they're all going to be synergistic and
• 40:00
  Speaker 2: coinciding together.
• 40:03
  Speaker 1: So which which would what would you stack with BPC
• 40:06
  Speaker 1: one fifty seven?
• 40:09
  Speaker 2: I would stack full fragment simosin b to four, otherwise
• 40:13
  Speaker 2: known as TB five hundred. Yeah, so I would also
• 40:18
  Speaker 2: stack GHK cus wow the copper pep exactly, and then
• 40:24
  Speaker 2: I would combine a growth hormone releasing pep dyde either
• 40:28
  Speaker 2: either something like c JC one two nine five blanded
• 40:31
  Speaker 2: with IPA morale in or either of those on their own,
• 40:35
  Speaker 2: or something like Sir Moralan as well, right hacka morale
• 40:40
  Speaker 2: and Tessa moralean. I don't, I don't. I haven't heard
• 40:43
  Speaker 2: that many good reviews about m K six seven seven.
• 40:47
  Speaker 2: I think I've heard it's a pretty m it's I've
• 40:54
  Speaker 2: heard it. It gives bad side effects, so I tend
• 40:56
  Speaker 2: to stick to the morale and growth hormone releasing tides.
• 41:02
  Speaker 1: Yeah, and so this obviously a hot subject today is
• 41:06
  Speaker 1: the semi glue tides and the how do you feel
• 41:12
  Speaker 1: about people taking the semi glue tides.
• 41:18
  Speaker 2: So I think that they've been wrongly villainized, and I
• 41:25
  Speaker 2: think that taken in the correct context at the at
• 41:29
  Speaker 2: a conservative dosage, at a conservative frequency, alongside a healthy
• 41:36
  Speaker 2: high protein diet, alongside high intensity workouts, alongside tantagrams of
• 41:42
  Speaker 2: creatine every day, alongside other anabolic healing PEP tides. So personally,
• 41:48
  Speaker 2: I don't recommend a GLP without recommending a growth horm
• 41:52
  Speaker 2: and releasing PEP tide taken alongside a GLP, because that
• 41:56
  Speaker 2: more or less offsets the muscle wasting. So there's a
• 42:00
  Speaker 2: lot of strategies that can be overcome when taking the glps.
• 42:06
  Speaker 2: And I think that you know those medications, they went
• 42:12
  Speaker 2: like to the masses, right, And whenever you have something
• 42:14
  Speaker 2: for the masses, you also have the media blowing the
• 42:17
  Speaker 2: medication out of proportion, especially with the celebrity the celebrity
• 42:24
  Speaker 2: paparazzi photos of celebrities who had taken the medication and
• 42:28
  Speaker 2: then they were looking very gaunt. And I think it
• 42:31
  Speaker 2: became a almost like a political statement. It became very
• 42:35
  Speaker 2: you know, political as well. And I think that it
• 42:38
  Speaker 2: was blown out of a portion. And I think when
• 42:39
  Speaker 2: used correctly, those are very good amino acid chains. And
• 42:44
  Speaker 2: I in my practice, I've never had someone come back
• 42:48
  Speaker 2: and say I had this really bad side of fact,
• 42:51
  Speaker 2: this went wrong. You know, I've had very good success.
• 42:53
  Speaker 2: And I think a lot of practitioners who truly used
• 42:56
  Speaker 2: glps and how they're meant to be used, I think
• 42:59
  Speaker 2: they feel the same way.
• 43:01
  Speaker 1: And just for everyone to understand, b l P is
• 43:04
  Speaker 1: a synonym for the semi glue tide. It's a g.
• 43:08
  Speaker 2: L P one, right, yeah, exactly.
• 43:11
  Speaker 1: And so what does g LP stand for?
• 43:14
  Speaker 4: A gamma's lucagon like pathway, dilecogen like pathway.
• 43:26
  Speaker 2: I don't, I don't. I don't use them too often.
• 43:30
  Speaker 2: I'm focused on the immune system. That's kind of my
• 43:33
  Speaker 2: brad and butter. But when I do use g LPs,
• 43:38
  Speaker 2: you know, I consult my colleagues and and we've never
• 43:43
  Speaker 2: had a boy experience. Well.
• 43:46
  Speaker 1: Also, let's not forget that the Insulin resistance is one
• 43:50
  Speaker 1: of the biggest causes of weight gain, and so the
• 43:56
  Speaker 1: original purpose of the g l P one semi gluey
• 43:59
  Speaker 1: is for or insulin control exactly, so that in itself
• 44:05
  Speaker 1: it could help people to lose weight if they get
• 44:07
  Speaker 1: that under control their blood sugar. So, yeah, what do
• 44:13
  Speaker 1: you feel though about the people that come back and
• 44:16
  Speaker 1: say I have to do I have to stay on
• 44:18
  Speaker 1: this from my entire life.
• 44:22
  Speaker 2: Yeah, I got that question from almost one in every
• 44:26
  Speaker 2: three individuals who are interested in peptides. The way I
• 44:30
  Speaker 2: explain it is that peptides are an arm of regenerative medicines.
• 44:35
  Speaker 2: So the peptides actually do regenerate healthy signaling cllular cascades
• 44:43
  Speaker 2: within the cells, so they regenerate healthy communication, healthy salular communication.
• 44:49
  Speaker 2: In theory, this should rebuild a new baseline level of
• 44:52
  Speaker 2: health for you during the peptide therapy. And if you
• 44:58
  Speaker 2: look after yourself and you maintain a very good lifestyle,
• 45:02
  Speaker 2: a good diet, and you should not really receive any
• 45:07
  Speaker 2: diminishing returns when you finish the peptide therapy. So you know,
• 45:12
  Speaker 2: you shouldn't have to be very dependent on the paptides.
• 45:15
  Speaker 2: You should be able to maintain more or lass that
• 45:19
  Speaker 2: baseline level of health that you've accomplished during the peptides.
• 45:22
  Speaker 2: So I always say, you know, the peptides, they're not
• 45:27
  Speaker 2: They don't act like a drug, so your cells don't
• 45:30
  Speaker 2: become dependent on them, so there's no diminishing returns. But
• 45:34
  Speaker 2: if you use the peptides and then when you stop,
• 45:36
  Speaker 2: you fall back into old habits, you get bitten by
• 45:39
  Speaker 2: a tick, you go, you'd start living in a moldy environment.
• 45:43
  Speaker 2: You know, you pick up an infectious disease. You know,
• 45:46
  Speaker 2: maybe you go through some psychosomatic stress and you become
• 45:50
  Speaker 2: inflamed again. Then your cells signaling capacity will eventually begin
• 45:55
  Speaker 2: to drop, and it may seem like you need to
• 45:57
  Speaker 2: become dependent on paptides, but it's not. Because the people
• 46:01
  Speaker 2: who maintain their healthy lifestyle and don't become inflamed, you know,
• 46:05
  Speaker 2: they're not dependent on pap tides. And usually the first
• 46:09
  Speaker 2: cycle to get them to that baseline to hit their goals,
• 46:13
  Speaker 2: you know, gets them there, and then from that they
• 46:15
  Speaker 2: actually use paptized as a hobby and as a way
• 46:18
  Speaker 2: to stay optimized or slowly tweak on their goals.
• 46:23
  Speaker 1: If someone wants to lose just five or ten pounds.
• 46:25
  Speaker 1: Would you ever let them usually semi gluta.
• 46:32
  Speaker 2: Yeah, you can do for example, one injection once every
• 46:36
  Speaker 2: two weeks.
• 46:38
  Speaker 1: Is that is that considered micro dosing? Yeah?
• 46:41
  Speaker 2: It is.
• 46:44
  Speaker 1: How much in that one dose that you do every
• 46:46
  Speaker 1: two weeks.
• 46:48
  Speaker 2: So I typically use the latest GLP and it's a
• 46:52
  Speaker 2: triple agonist and it's called ratitrue Tide. So I've I've
• 46:57
  Speaker 2: kind of moved on from the salmon glue tie, which
• 47:00
  Speaker 2: is the Ozambic and the gobi, which is theatre's appetite,
• 47:05
  Speaker 2: and I tend to use the ratitrude Tide. It's a
• 47:08
  Speaker 2: pretty like bleeding edge glps. It's a triple agonist, and
• 47:15
  Speaker 2: that one we use it as when we use it
• 47:17
  Speaker 2: at one thousand, two hundred and fifty mcg beginning and
• 47:23
  Speaker 2: a very conservative dosage of maybe once every two weeks,
• 47:27
  Speaker 2: and then from there you can build up because a
• 47:29
  Speaker 2: lot of people, they have a lot of resistance with
• 47:32
  Speaker 2: these glps and it's always better to, you know, start
• 47:36
  Speaker 2: the person very very slow, just just to reassure them,
• 47:40
  Speaker 2: make them feel comfortable, and once they may realize that
• 47:43
  Speaker 2: they're not gonna blow up after the injection, you can
• 47:47
  Speaker 2: slowly start increasing them.
• 47:49
  Speaker 1: Is that intramuscular, the injection.
• 47:53
  Speaker 2: It can be. So there's a few different injection sites.
• 47:56
  Speaker 2: You can do the fire, you can do like the
• 47:59
  Speaker 2: love handle, upper glute tried and try agone, you can
• 48:06
  Speaker 2: do the you can do around the valley button. Personally,
• 48:09
  Speaker 2: for me, I've always preferred to inject in my glute trygone.
• 48:14
  Speaker 2: But I know a lot of people inject around the
• 48:16
  Speaker 2: valley button, which would be considered subcutaneous career.
• 48:21
  Speaker 1: So, can people work with you, Jessica if they're interested at.
• 48:28
  Speaker 2: With cell medicine, Yeah, yeah, for sure. So I'm based
• 48:33
  Speaker 2: in Dubai and I am taking on clients at a
• 48:37
  Speaker 2: limited capacity because I'm doing my masters and I'm also
• 48:41
  Speaker 2: building out a few Pepti brands. But I am taking
• 48:44
  Speaker 2: on clients and also we have I have my main
• 48:48
  Speaker 2: partner clinic in London, so anyone in the UK can
• 48:51
  Speaker 2: go to the clinic in London and can be seen
• 48:54
  Speaker 2: face to face. And I also have some partner in
• 48:57
  Speaker 2: clinics also in Tokyo and here in Dubai as well,
• 49:01
  Speaker 2: and also in Switzerland too. So what's the name of
• 49:06
  Speaker 2: the clinic, Oh, the one in London, It's called Neutro
• 49:10
  Speaker 2: Neutral Clinic.
• 49:11
  Speaker 1: And U tro neutro.
• 49:14
  Speaker 2: Yeah, and you U t r O. That's right. But
• 49:17
  Speaker 2: I can do I can do Talahal or we can
• 49:22
  Speaker 2: we can see you in London if you prefer more
• 49:24
  Speaker 2: hands on service.
• 49:26
  Speaker 1: Right, And so if somebody's in the US, though, which
• 49:29
  Speaker 1: is you know, probably seventy percent of our viewers, they
• 49:33
  Speaker 1: would have to do telemedicine if they're not coming to
• 49:35
  Speaker 1: London or Dubai or Geneva.
• 49:38
  Speaker 2: Yeah. I've seen more than probably four hundred clients now
• 49:43
  Speaker 2: via Talahal Palam Madison, So I can definitely see people
• 49:49
  Speaker 2: in the US. I can get the PAPTI shipped to
• 49:51
  Speaker 2: you within the US. I have very good suppliers within
• 49:55
  Speaker 2: the US. I can we can do everything remotely. I
• 49:58
  Speaker 2: have all of my professional qualifications on my LinkedIn, I
• 50:03
  Speaker 2: have client testimonial, video testimonials on my Twitter, will act
• 50:08
  Speaker 2: on Instagram, on YouTube, and also I think we're going
• 50:12
  Speaker 2: to link one of my presentations at the bottom of
• 50:15
  Speaker 2: the podcast as well, so you can also see my
• 50:18
  Speaker 2: written work and you can you can have a deep
• 50:20
  Speaker 2: dive into peptides for biological age and oral biregulated for
• 50:24
  Speaker 2: biological age as well.
• 50:26
  Speaker 1: Yeah, we're gonna I think what we'll do since we're
• 50:28
  Speaker 1: not doing a video today. I think what we're going
• 50:30
  Speaker 1: to do is have you put this, We'll put this
• 50:32
  Speaker 1: in the show notes your presentation.
• 50:35
  Speaker 2: Yeah.
• 50:36
  Speaker 1: Cool, So I'm saying that on air right now so
• 50:39
  Speaker 1: that my assistant makes sure that she gets the presentation
• 50:43
  Speaker 1: from you and then adds it to the show notes
• 50:45
  Speaker 1: for our viewers. So if you'll take care of that
• 50:49
  Speaker 1: with Roxanne after the show, I would appreciate it.
• 50:53
  Speaker 2: Amazing.
• 50:54
  Speaker 1: Yeah, So what do you require when you start working
• 50:58
  Speaker 1: with a client or patient? What do they have to
• 51:02
  Speaker 1: give you? If it's tell and medicine.
• 51:05
  Speaker 2: I mean, I'm pretty flexible, so I don't necessarily believe
• 51:10
  Speaker 2: that peptides should be dependent on blood test results. There's
• 51:16
  Speaker 2: nothing really in a blood test result that would say, okay,
• 51:20
  Speaker 2: you have this market elevated or decreased, So therefore we
• 51:24
  Speaker 2: need to use BPC one five salent. And I think
• 51:26
  Speaker 2: that's a common misconception of clients. They think that they
• 51:30
  Speaker 2: need to get a whole battery of tests for peptides,
• 51:33
  Speaker 2: whereas actually I like to be a bit more open
• 51:35
  Speaker 2: minded and just kind of I will ask, you know,
• 51:40
  Speaker 2: a relatively basic intake form. So what are your goals,
• 51:43
  Speaker 2: what are your symptoms, what you feel intuitively you're struggling with,
• 51:47
  Speaker 2: you know, what is your past, what other therapies have
• 51:50
  Speaker 2: you tried? And from that I can put together a
• 51:54
  Speaker 2: pretty in depth protocol, typically five to six injactibles, one
• 52:00
  Speaker 2: to two oral. We can also then use one to
• 52:03
  Speaker 2: two intrinasal and then also depending on the investment that
• 52:07
  Speaker 2: someone would like to make into the protocol, as in
• 52:10
  Speaker 2: the peptide course, we can also add the bioregulators in
• 52:13
  Speaker 2: there as well, so you know, you don't really need
• 52:17
  Speaker 2: too much to start peptides because there's no correlation between
• 52:22
  Speaker 2: a task market and a specific peptide.
• 52:27
  Speaker 1: Have you ever experienced any negative side effic where somebody
• 52:33
  Speaker 1: you know should never take a pep tide in terms
• 52:36
  Speaker 1: of their.
• 52:37
  Speaker 2: Health condition, not thus far. So the main body of
• 52:45
  Speaker 2: my work is looking at models of immunocompromisation, so that
• 52:50
  Speaker 2: is typically within that bracket, are you know, chronically toxic,
• 52:55
  Speaker 2: chronically sick people with mold illness, with lime disease. Those
• 53:01
  Speaker 2: people are very sensitive individuals, and they're very sensitive to
• 53:05
  Speaker 2: supplements and you know, even to just chemicals in their
• 53:09
  Speaker 2: daily environment. And all of those people have tolerated peptides
• 53:14
  Speaker 2: extremely well and have done very well on the peptides.
• 53:19
  Speaker 2: I have had a few people, a handful of people
• 53:23
  Speaker 2: who have been treatment resistant. So no matter you know,
• 53:27
  Speaker 2: what peptides we've used, we haven't managed to get the
• 53:31
  Speaker 2: results that we've been looking for. But this can be
• 53:34
  Speaker 2: attributed to maybe biofilms, because if you have biofilms around
• 53:39
  Speaker 2: your impacted area of cells, it's going to be difficult,
• 53:43
  Speaker 2: difficult to get any active into those cells. So I
• 53:47
  Speaker 2: have had people who've been treatment resistant, but you know,
• 53:51
  Speaker 2: we have tried all the way and we have got
• 53:53
  Speaker 2: in some way, but you know, not the same results
• 53:55
  Speaker 2: as the majority of my clients.
• 53:58
  Speaker 1: And how are you defining by film?
• 54:02
  Speaker 2: So biofilm is typically a reservoir of I think it's
• 54:07
  Speaker 2: made up of chiten. Uh, So you know, chiten is
• 54:11
  Speaker 2: like this gelatinous glue that these bacterial, viral, fungal, parasitic
• 54:21
  Speaker 2: reservoirs they all come together and they make these biofilms.
• 54:25
  Speaker 2: It's very common in long standing gut issues, in U
• 54:29
  Speaker 2: T I issues, bladder issues. It's actually dary common for
• 54:35
  Speaker 2: the E. N T as well, and also the COVID
• 54:38
  Speaker 2: virus was known to have a very high biofilm generating
• 54:44
  Speaker 2: you know genome's studies on that.
• 54:46
  Speaker 1: Now and how does one know that they have that condition?
• 54:51
  Speaker 2: If you have a biofilm, if you're you know, dary
• 54:56
  Speaker 2: treatment resistant and you have been for years, and you're
• 55:00
  Speaker 2: symptoms come in waves, cyclical waves, so you know every
• 55:05
  Speaker 2: three months or every six months, you know, very cyclical
• 55:08
  Speaker 2: waves almost like correlated to the moons and the seasons changing,
• 55:15
  Speaker 2: then you're more likely to have a biofilm. So if
• 55:17
  Speaker 2: you have a symptom increase, then around these cyclical waves,
• 55:21
  Speaker 2: you're more likely to have a biofilm because bacteria and
• 55:25
  Speaker 2: all the living pathogens in the biofilm have their own
• 55:29
  Speaker 2: life cycle. When this life cycle goes through its stages,
• 55:33
  Speaker 2: they break out on the biofilm and they cause an
• 55:35
  Speaker 2: increase in symptoms. A whole it's a whole other, very
• 55:38
  Speaker 2: scary topic.
• 55:40
  Speaker 1: Yeah, Well, I know you've done a lot of work
• 55:43
  Speaker 1: with mold and lime, So is that a clue to
• 55:48
  Speaker 1: you right away with somebody who's dealing with mold or
• 55:52
  Speaker 1: lime disease that they also have the biofilm issues that
• 55:57
  Speaker 1: are going to prevent any treatment from being efficacious.
• 56:01
  Speaker 2: Yeah, it can. It can depend. So line itself is
• 56:05
  Speaker 2: known to cause a lot of fibrotic cysts, so line
• 56:10
  Speaker 2: actually will make cysts and it will hide in the
• 56:12
  Speaker 2: cysts and they mix these with fibrin, so that can
• 56:17
  Speaker 2: be pretty difficult. And then also, yeah, people people who
• 56:21
  Speaker 2: are you know, chronically sick, you know, they've been proven
• 56:25
  Speaker 2: to have very high bio biofilm reservoirs. So I do
• 56:29
  Speaker 2: see that commonly. And you know, if someone is sorry,
• 56:33
  Speaker 2: treatment resistant, you you can kind of get a sense
• 56:37
  Speaker 2: for it, and you can you can put them on
• 56:40
  Speaker 2: maybe two to three months of biophone busters before starting
• 56:43
  Speaker 2: any paptech therapy protocol.
• 56:46
  Speaker 1: Mh so J justica. They just they just flagged me
• 56:52
  Speaker 1: that we're running out of China, And I want to
• 56:55
  Speaker 1: ask you a couple other questions before we go. What
• 56:58
  Speaker 1: do you think is the few sure of peptide and
• 57:01
  Speaker 1: peptid bioregulators.
• 57:05
  Speaker 2: So actually, I think the human genome has around three
• 57:10
  Speaker 2: hundred thousand peptide is available to code to translate into proteins,
• 57:17
  Speaker 2: which are what you know, peptides are anything that's made
• 57:20
  Speaker 2: up of an amino acid is a protein. And really,
• 57:24
  Speaker 2: I mean, how many do we actually have on the
• 57:27
  Speaker 2: bench on the bad side. So you know how many
• 57:31
  Speaker 2: are community available for people to buy. I think thirty
• 57:35
  Speaker 2: five maybe not even that. The bioregulator is a twenty one,
• 57:40
  Speaker 2: so it's under one hundred peptides and bioregulators combined that
• 57:45
  Speaker 2: you can go on the internet or get prescribed and
• 57:48
  Speaker 2: treat yourself with. So I think the future is actually
• 57:53
  Speaker 2: figuring out which amino acid chains they're going to bring
• 57:56
  Speaker 2: about the greatest success to human health, creating more of
• 58:00
  Speaker 2: those reducing barriers between in vitro to vitro to human
• 58:07
  Speaker 2: clinical trials of these amino acid chains, and then also
• 58:12
  Speaker 2: exploring peptides from b venom to the d MT frog two,
• 58:19
  Speaker 2: you know, other animals who have had like tribal medicinal impacts,
• 58:27
  Speaker 2: and also bringing those peptides to humans as well, because
• 58:31
  Speaker 2: I know in traditional Chinese medicine, b venom is huge, right,
• 58:35
  Speaker 2: and I really agree with b vanoms, so you know,
• 58:38
  Speaker 2: there should be a b vanom peptide. There's also there
• 58:41
  Speaker 2: also should be a lot more peptides for people with
• 58:43
  Speaker 2: spinal cord injuries as well.
• 58:47
  Speaker 1: Good point, Well, they're using stem cells for spinal cord injuries,
• 58:53
  Speaker 1: but there is. You're right, there's there are not a
• 58:56
  Speaker 1: lot of peptides to focus on the spinal cord.
• 59:00
  Speaker 2: I wonder why that is or the brain. I mean,
• 59:03
  Speaker 2: we have three bro lisin and called taxin, but they're
• 59:06
  Speaker 2: not exactly super specialized. They're just blanded down pig and
• 59:11
  Speaker 2: cow peptides.
• 59:13
  Speaker 1: M hm. So yes, good. How how can somebody who's
• 59:20
  Speaker 1: interested reach you?
• 59:24
  Speaker 2: My website is Jessica Alana dot com, my email is
• 59:29
  Speaker 2: Jessica Jaska Alana dot com, and my Instagram is Jessica
• 59:33
  Speaker 2: Alana And I'm sure we'll have all of that in
• 59:36
  Speaker 2: the show notes and it'll also be the first slide
• 59:39
  Speaker 2: on my linked presentation as well. So yeah, you can
• 59:42
  Speaker 2: reach to me. You can either reach it out to
• 59:44
  Speaker 2: me via my email or you can use the contact
• 59:48
  Speaker 2: form on my website, or if you want to do
• 59:51
  Speaker 2: more of a deep dive, you can search me on LinkedIn.
• 59:54
  Speaker 2: You can search me on Twitter, on Instagram, on YouTube
• 59:57
  Speaker 2: you can see everything and all my proof of work.
• 1:00:00
  Speaker 1: And Jessica, have you seen the latest issue of Top
• 1:00:04
  Speaker 1: Doctor Magazine?
• 1:00:07
  Speaker 2: I don't think I have. I we don't get a
• 1:00:11
  Speaker 2: lot of exposure to medical magazines here in Dubai. It's
• 1:00:15
  Speaker 2: a very different community here.
• 1:00:19
  Speaker 1: Well you can. I think you can view it online.
• 1:00:22
  Speaker 1: The reason I'm asking is that I didn't. You're writing
• 1:00:25
  Speaker 1: a monthly column for Top Doctor magazine and I just
• 1:00:28
  Speaker 1: did my first interview with a cover of Jay Campbell.
• 1:00:33
  Speaker 2: Oh I love him.
• 1:00:34
  Speaker 1: Yeah, So I would love if you would watch or
• 1:00:40
  Speaker 1: read the interview because he is now a co founder
• 1:00:44
  Speaker 1: of Biolongevity Labs, which is taking doctor Cavinson's research into
• 1:00:51
  Speaker 1: the US manufacturing of peptide bioregulators. So they yeah, peptides
• 1:00:58
  Speaker 1: as well, but and some some oral and mostly injectable.
• 1:01:02
  Speaker 1: But I think you find the interview fascinating if you
• 1:01:07
  Speaker 1: have a chance to catch it, or I could ask
• 1:01:09
  Speaker 1: for If you can't find it, let me know and
• 1:01:12
  Speaker 1: I'll have my assistant send you the link.
• 1:01:16
  Speaker 2: In fact, I have a lot of respect for j
• 1:01:21
  Speaker 2: He had you know, he was He's basically the o
• 1:01:24
  Speaker 2: G of the peptide industry, So I have a lot
• 1:01:26
  Speaker 2: of respect for him. He was talking about pep tid's
• 1:01:30
  Speaker 2: like ten to fifteen years ago. Oh yeah, yeah.
• 1:01:34
  Speaker 1: He wrote the Bible. He's been on my podcast couple
• 1:01:38
  Speaker 1: and I've been on his. So we did a mutual
• 1:01:40
  Speaker 1: reciprocal appearances, and then he stopped doing his podcast when
• 1:01:45
  Speaker 1: he became an entrepreneur in the in the startup world.
• 1:01:51
  Speaker 1: So we don't we're not doing the podcast with him recipically,
• 1:01:56
  Speaker 1: but we did select him as my first article. And
• 1:02:01
  Speaker 1: the reason is that because peptides have become such a
• 1:02:04
  Speaker 1: hot topic and he is like the granddad. He particularly testosterone.
• 1:02:09
  Speaker 1: He wrote the Bible, yeah, way back and I think
• 1:02:12
  Speaker 1: it was twenty ten or something. He wrote the Bible
• 1:02:15
  Speaker 1: before it was even such a hot topic. And that
• 1:02:21
  Speaker 1: that book his original book. He's written six different books.
• 1:02:25
  Speaker 1: But I told him, I said, Jay, I don't know
• 1:02:27
  Speaker 1: how you ever sleep because he's so prolific. But that
• 1:02:32
  Speaker 1: original testosterone Bible is still being used today.
• 1:02:37
  Speaker 2: He's awesome.
• 1:02:39
  Speaker 1: And he's not a medical doctor. He's a you know,
• 1:02:41
  Speaker 1: he's a just like Bill Lawrence and me and myself.
• 1:02:44
  Speaker 1: We're all real estate developers. Interesting. I morphed into the
• 1:02:51
  Speaker 1: functional medicine field, a longevity field, really through experiences in
• 1:02:57
  Speaker 1: our own personal lives, just like you did.
• 1:03:01
  Speaker 2: Yeah, I don't. I wouldn't discredit anyone for not being
• 1:03:06
  Speaker 2: a medical doctor. I'm not a medical doctor. You know.
• 1:03:09
  Speaker 2: My bachelor's is biomedicine. My master's is longevity science. I
• 1:03:13
  Speaker 2: don't have a I'm not licensed to practice medicine. I
• 1:03:16
  Speaker 2: wouldn't discredit anyone for being a medical doctor. Knowledge is knowledge,
• 1:03:21
  Speaker 2: and if you can show true understanding and you can
• 1:03:24
  Speaker 2: help people and you'll gather, you'll gather people who trust
• 1:03:28
  Speaker 2: you and you'll help them. That's just how it goes.
• 1:03:30
  Speaker 1: No. Yeah, and my good friend Lisa Tomati, who you
• 1:03:35
  Speaker 1: should be on her podcast called Pushing the Limits. I'll
• 1:03:38
  Speaker 1: introduce you. But she's not a medical dator, but she
• 1:03:42
  Speaker 1: does hyperbaric She has a whole chamber in her I
• 1:03:46
  Speaker 1: mean she has a number of different hyperbaric chambers than
• 1:03:50
  Speaker 1: her clinic. But she's another good example of people someone
• 1:03:55
  Speaker 1: like you just studied and studied and has had a
• 1:03:59
  Speaker 1: consulting practice. All right, Well we've run out of time,
• 1:04:02
  Speaker 1: and I just thank you so much. I wish you're
• 1:04:05
  Speaker 1: the absolute very best. I'm going to talk to you offline. Yeah,
• 1:04:10
  Speaker 1: these connections and and anything else we can I can
• 1:04:14
  Speaker 1: do for you or you can do for me, well
• 1:04:16
  Speaker 1: find the path forward.
• 1:04:18
  Speaker 2: So well, thank you so much.
• 1:04:20
  Speaker 1: And I'll let you know what happens with Bill Lawrence
• 1:04:24
  Speaker 1: and the next phase of the clinical trials. I'm really
• 1:04:27
  Speaker 1: looking forward to hearing you about your experience as you
• 1:04:30
  Speaker 1: progress forward with him.
• 1:04:33
  Speaker 2: So I'm so excited. Yeah, we'll talk very soon. We
• 1:04:37
  Speaker 2: planned this for a while.
• 1:04:38
  Speaker 1: Ask you, Jessica. You've been very patient with us, and.
• 1:04:44
  Speaker 2: Oh you too.
• 1:04:45
  Speaker 1: Thank you. All right, well you have a good night's sleep,
• 1:04:48
  Speaker 1: and thank you so much taking the time so late
• 1:04:51
  Speaker 1: in your evening to be with us, and my pleasure
• 1:04:54
  Speaker 1: cate all of your knowledge and sharing with us today.
• 1:04:58
  Speaker 1: Thank you again, Jessica.
• 1:05:00
  Speaker 2: Thank you so much.
• 1:05:01
  Speaker 1: Okay, bye, bye bye